The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.

Priority review for Welireg is based on data from the Phase II LITESPARK-015 trial, which showed promising response rates in ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

president of Merck Research Laboratories, said in a statement. Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

Merck Research Laboratories. “We look forward to advancing our research of this investigational ROR1-directed antibody drug conjugate, which we believe has strong potential in multiple ...

Merck Research Laboratories. “We continue to believe LAGEVRIO may be an important option for people with risk factors like older age, multiple comorbidities, and immunocompromising conditions ...

Merck, a leading science and technology company, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement to automate assay kits on a custom ...

A recent health news roundup explores legal, financial, and strategic developments. Highlights include Robert F. Kennedy ...